French radiopharmaceutical developer IBA Molecular has received approval to market its Filtracis radiopharmaceutical kit in France.
Filtracis is designed for diagnosing kidney and urinary tract malfunctions, and it also displays dosimetry for pediatric use, according to the Gif-sur-Yvette-based division of Ion Beam Applications (IBA).
Through the European Union's mutual recognition procedure, IBA Molecular plans to extend the Filtracis marketing approval to other European countries. The first approvals are expected before the end of 2011, IBA Molecular said.
Related Reading
IBA lands Russian order, October 13, 2010
IBA inks Tc-99m deal, sells prototype, September 2, 2010
IBA considers IPO for pharma unit, August 31, 2010
IBA, Bayer ink imaging deal, August 27, 2010
IBA to build proton center in Poland, August 2, 2010
Copyright © 2010 AuntMinnie.com
